Supplementary Material for: The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives
Aspirin and other non-steroidal anti-inflammatory
drugs (NSAIDs) have received considerable interest as
potential chemopreventive agents. The aim of this review
is to summarize the accumulated knowledge on
the effect of NSAIDs on breast cancer incidence and
natural history, and the underlying pathophysiology.
NSAIDs mainly block inflammation by inhibiting cyclooxygenase
enzymes, leading to lower prostaglandin
synthesis. The latter has been reported to affect breast
cancer risk through hormonal and inflammation-related
pathways. Intensity, dose, frequency, duration,
and timing of administration may also be significant.
There is currently enough evidence to support a role of
NSAIDs in breast cancer prevention and relapse, which
deserves further large-scale experimental and clinical
investigation.